Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
60 Degrees Pharmaceuticals, Inc. ( (SXTP) ) has provided an announcement.
On July 15, 2025, 60 Degrees Pharmaceuticals, Inc. announced a Securities Purchase Agreement with institutional investors for a follow-on offering, which included shares of common stock and various warrants. The offering, which closed on July 16, 2025, generated approximately $5 million in gross proceeds, intended for general corporate purposes and working capital. The offering was made under the company’s registration statement declared effective by the SEC. This move is expected to impact the company’s financial operations and market positioning by providing additional capital for its ongoing projects.
The most recent analyst rating on (SXTP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.
Spark’s Take on SXTP Stock
According to Spark, TipRanks’ AI Analyst, SXTP is a Underperform.
SXTP is currently facing substantial financial challenges, with declining revenues and negative profitability being the most significant factors impacting its score. Technical analysis supports a bearish outlook, with the stock trading below key moving averages and showing potential oversold conditions. The valuation remains unattractive due to a negative P/E ratio and lack of dividend yield.
To see Spark’s full report on SXTP stock, click here.
More about 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company achieved FDA approval for its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018. It collaborates with research organizations in the U.S., Australia, and Singapore, and is supported by the U.S. Department of Defense and private investors, including Knight Therapeutics Inc. The company is headquartered in Washington D.C., with a subsidiary in Australia.
Average Trading Volume: 649,700
Technical Sentiment Signal: Sell
Current Market Cap: $2.42M
Learn more about SXTP stock on TipRanks’ Stock Analysis page.